Elkanah Omenge Orang'o1, Tao Liu, Astrid Christoffersen-Deb, Peter Itsura, John Oguda, Sierra Washington, David Chumba, Latha Pisharodi, Susan Cu-Uvin, Anne F Rositch. 1. aAcademic Model Providing Access to Healthcare (AMPATH) Partnership bDepartment of Reproductive Health, School of Medicine, College of Health Sciences, Moi University, Eldoret, Kenya cDepartment of Biostatistics, Center for Statistical Science, Brown University School of Public Health, Providence, Rhode Island, USA dDepartment of Obstetrics & Gynaecology, University of Toronto, Toronto, Ontario, Canada eDepartment of Pathology, Brown University, Providence, Rhode Island, USA fDepartment of Pathology, School of Medicine, College of Health Sciences, Moi University, Eldoret, Kenya gDepartment of Obstetrics and Gynecology, The Miriam Hospital, Brown University, Providence, Rhode Island hDepartment of Epidemiology, Johns Hopkins Bloomberg School of Public Health, Baltimore, Maryland, USA.
Abstract
OBJECTIVES: Few studies have addressed optimal follow-up for HIV-infected women after cervical treatment. This study aimed to compare performance of three available tests to detect posttreatment cervical disease in HIV-infected women in Kenya. DESIGN: This is a prospective cohort study. METHODS: At least 6 months following cryotherapy, 517 HIV-infected women were evaluated concurrently with visual inspection with acetic acid (VIA), papanicolaou (Pap) smear, and high-risk human papillomavirus (HR-HPV) testing. Women positive by any test (≥low-grade squamous intraepithelial lesion for Pap) were scheduled for colposcopy and biopsy. Among 248 with histological confirmation [and 174 assumed to be truly negative for cervical intraepithelial neoplasia (CIN)2+ after testing negative by all three tests], the ability of each test alone, or in combination, to detect CIN2+ was calculated to determine their utility in posttreatment follow-up. RESULTS: The median age of women was 35 years, 68% were WHO stage 1-2, with a median CD4 cell count of 410 cells/μl, and 87% were on combination antiretroviral therapy. At a median of 6.3 months posttreatment, 64% had an abnormal screen by VIA, Pap, and/or HR-HPV. Among women with histological confirmation, 72 (30%) had persistent/recurrent CIN2+. As single tests, Pap correctly classified the most cases (83%) and had the highest specificity [91% (88 and 95%); sensitivity 44% (35 and 53%)], whereas HR-HPV had the highest sensitivity [85% (75 and 96%); specificity 54% (49 and 58%)]. VIA was not sensitive [27% (18 and 36%)] for the detection of posttreatment CIN2+ [specificity 82% (79 and 86%)]. CONCLUSION: With the goal to minimize the number of false negatives (e.g. not miss CIN2+ posttreatment) in this population that is high-risk due to both prior cervical disease and HIV infection, HR-HPV-based algorithms are recommended.
OBJECTIVES: Few studies have addressed optimal follow-up for HIV-infectedwomen after cervical treatment. This study aimed to compare performance of three available tests to detect posttreatment cervical disease in HIV-infectedwomen in Kenya. DESIGN: This is a prospective cohort study. METHODS: At least 6 months following cryotherapy, 517 HIV-infectedwomen were evaluated concurrently with visual inspection with acetic acid (VIA), papanicolaou (Pap) smear, and high-risk human papillomavirus (HR-HPV) testing. Women positive by any test (≥low-grade squamous intraepithelial lesion for Pap) were scheduled for colposcopy and biopsy. Among 248 with histological confirmation [and 174 assumed to be truly negative for cervical intraepithelial neoplasia (CIN)2+ after testing negative by all three tests], the ability of each test alone, or in combination, to detect CIN2+ was calculated to determine their utility in posttreatment follow-up. RESULTS: The median age of women was 35 years, 68% were WHO stage 1-2, with a median CD4 cell count of 410 cells/μl, and 87% were on combination antiretroviral therapy. At a median of 6.3 months posttreatment, 64% had an abnormal screen by VIA, Pap, and/or HR-HPV. Among women with histological confirmation, 72 (30%) had persistent/recurrent CIN2+. As single tests, Pap correctly classified the most cases (83%) and had the highest specificity [91% (88 and 95%); sensitivity 44% (35 and 53%)], whereas HR-HPV had the highest sensitivity [85% (75 and 96%); specificity 54% (49 and 58%)]. VIA was not sensitive [27% (18 and 36%)] for the detection of posttreatment CIN2+ [specificity 82% (79 and 86%)]. CONCLUSION: With the goal to minimize the number of false negatives (e.g. not miss CIN2+ posttreatment) in this population that is high-risk due to both prior cervical disease and HIV infection, HR-HPV-based algorithms are recommended.
Authors: Lynette Denny; Louise Kuhn; Michelle De Souza; Amy E Pollack; William Dupree; Thomas C Wright Journal: JAMA Date: 2005-11-02 Impact factor: 56.272
Authors: Sara E Forhan; Catherine C Godfrey; D Heather Watts; Carol L Langley Journal: J Acquir Immune Defic Syndr Date: 2015-04-15 Impact factor: 3.731
Authors: Jenell S Coleman; Michelle S Cespedes; Susan Cu-Uvin; Rose J Kosgei; May Maloba; Jean Anderson; Timothy Wilkin; Antoine Jaquet; Julia Bohlius; Kathryn Anastos; Kara Wools-Kaloustian Journal: J Low Genit Tract Dis Date: 2016-01 Impact factor: 1.925
Authors: R Sankaranarayanan; R Rajkumar; P O Esmy; J M Fayette; S Shanthakumary; L Frappart; S Thara; J Cherian Journal: Br J Cancer Date: 2007-02-20 Impact factor: 7.640
Authors: Cynthia Firnhaber; Nomtha Mayisela; Lu Mao; Sophie Williams; Avril Swarts; Mark Faesen; Simon Levin; Pam Michelow; Tanvier Omar; Michael G Hudgens; Anna-Lise Williamson; Bruce Allan; David A Lewis; Jennifer S Smith Journal: PLoS One Date: 2013-01-11 Impact factor: 3.240
Authors: Y Tong; E Orang'o; M Nakalembe; P Tonui; P Itsura; K Muthoka; M Titus; S Kiptoo; A Mwangi; J Ong'echa; R Tonui; B Odongo; C Mpamani; B Rosen; A Moormann; S Cu-Uvin; J A Bailey; C I Oduor; A Ermel; C Yiannoutsos; B Musick; E Sang; A Ngeresa; G Banturaki; A Kiragga; J Zhang; Y Song; S Chintala; R Katzenellenbogen; P Loehrer; D R Brown Journal: Ann Med Date: 2022-12 Impact factor: 5.348
Authors: Phuong Lien Tran; Bruno Kenfack; Eveline Tincho Foguem; Manuela Viviano; Liliane Temogne; Pierre-Marie Tebeu; Rosa Catarino; Anne-Caroline Benski; Pierre Vassilakos; Patrick Petignat Journal: Int J Womens Health Date: 2017-12-01
Authors: Manuela Viviano; Phuong Lien Tran; Bruno Kenfack; Rosa Catarino; Mohamed Akaaboune; Liliane Temogne; Eveline Tincho Foguem; Pierre Vassilakos; Patrick Petignat Journal: Int J Womens Health Date: 2018-04-11